TISIDB

Summary
Symbol	MSN
Name	moesin
Aliases	HEL70; epididymis luminal protein 70; membrane-organizing extension spike protein
Chromosomal Location	Xq11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Peripheral membrane protein Cytoplasmic side Cytoplasm, cytoskeleton Apical cell membrane Peripheral membrane protein Cytoplasmic side Cell projection, microvillus membrane Peripheral membrane protein Cytoplasmic side Cell projection, microvillus Note=Phosphorylated form is enriched in microvilli-like structures at apical membrane. Increased cell membrane localization of both phosphorylated and non-phosphorylated forms seen after thrombin treatment (By similarity).
Domain	PF00769 Ezrin/radixin/moesin family PF09380 FERM C-terminal PH-like domain PF00373 FERM central domain PF09379 FERM N-terminal domain
Function	Probably involved in connections of major cytoskeletal structures to the plasma membrane. May inhibit herpes simplex virus 1 infection at an early stage. Plays a role in regulating the proliferation, migration, and adhesion of human lymphoid cells and participates in immunologic synapse formation (PubMed:27405666).

> Gene Ontology [ TOP ]
Biological Process	GO:0001738 morphogenesis of a polarized epithelium GO:0001885 endothelial cell development GO:0002064 epithelial cell development GO:0002685 regulation of leukocyte migration GO:0003158 endothelium development GO:0007034 vacuolar transport GO:0007159 leukocyte cell-cell adhesion GO:0007163 establishment or maintenance of cell polarity GO:0008360 regulation of cell shape GO:0008361 regulation of cell size GO:0009894 regulation of catabolic process GO:0009896 positive regulation of catabolic process GO:0016197 endosomal transport GO:0016482 cytosolic transport GO:0022406 membrane docking GO:0022604 regulation of cell morphogenesis GO:0022612 gland morphogenesis GO:0022614 membrane to membrane docking GO:0030010 establishment of cell polarity GO:0030859 polarized epithelial cell differentiation GO:0031329 regulation of cellular catabolic process GO:0031331 positive regulation of cellular catabolic process GO:0031334 positive regulation of protein complex assembly GO:0032386 regulation of intracellular transport GO:0032388 positive regulation of intracellular transport GO:0032535 regulation of cellular component size GO:0033574 response to testosterone GO:0035088 establishment or maintenance of apical/basal cell polarity GO:0035089 establishment of apical/basal cell polarity GO:0036010 protein localization to endosome GO:0042176 regulation of protein catabolic process GO:0043254 regulation of protein complex assembly GO:0044089 positive regulation of cellular component biogenesis GO:0045022 early endosome to late endosome transport GO:0045197 establishment or maintenance of epithelial cell apical/basal polarity GO:0045198 establishment of epithelial cell apical/basal polarity GO:0045446 endothelial cell differentiation GO:0045732 positive regulation of protein catabolic process GO:0048732 gland development GO:0050900 leukocyte migration GO:0060627 regulation of vesicle-mediated transport GO:0061028 establishment of endothelial barrier GO:0061162 establishment of monopolar cell polarity GO:0061245 establishment or maintenance of bipolar cell polarity GO:0061339 establishment or maintenance of monopolar cell polarity GO:0071394 cellular response to testosterone stimulus GO:0071396 cellular response to lipid GO:0071407 cellular response to organic cyclic compound GO:0071800 podosome assembly GO:0071801 regulation of podosome assembly GO:0071803 positive regulation of podosome assembly GO:0072665 protein localization to vacuole GO:0072676 lymphocyte migration GO:0090066 regulation of anatomical structure size GO:0090162 establishment of epithelial cell polarity GO:0098927 vesicle-mediated transport between endosomal compartments GO:1901654 response to ketone GO:1901655 cellular response to ketone GO:1902115 regulation of organelle assembly GO:1902117 positive regulation of organelle assembly GO:1902946 protein localization to early endosome GO:1902965 regulation of protein localization to early endosome GO:1902966 positive regulation of protein localization to early endosome GO:1903335 regulation of vacuolar transport GO:1903337 positive regulation of vacuolar transport GO:1903362 regulation of cellular protein catabolic process GO:1903364 positive regulation of cellular protein catabolic process GO:1903649 regulation of cytoplasmic transport GO:1903651 positive regulation of cytoplasmic transport GO:1903829 positive regulation of cellular protein localization GO:2000401 regulation of lymphocyte migration GO:2000641 regulation of early endosome to late endosome transport GO:2000643 positive regulation of early endosome to late endosome transport
Molecular Function	GO:0003725 double-stranded RNA binding GO:0003779 actin binding GO:0005200 structural constituent of cytoskeleton GO:0050839 cell adhesion molecule binding
Cellular Component	GO:0001931 uropod GO:0005902 microvillus GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0016323 basolateral plasma membrane GO:0016324 apical plasma membrane GO:0019898 extrinsic component of membrane GO:0030055 cell-substrate junction GO:0030175 filopodium GO:0031143 pseudopodium GO:0031253 cell projection membrane GO:0031254 cell trailing edge GO:0031528 microvillus membrane GO:0043209 myelin sheath GO:0045177 apical part of cell GO:0072562 blood microparticle GO:0098858 actin-based cell projection

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04530 Tight junction hsa04670 Leukocyte transendothelial migration hsa04810 Regulation of actin cytoskeleton
Reactome	R-HSA-422475: Axon guidance R-HSA-1266738: Developmental Biology R-HSA-373760: L1CAM interactions R-HSA-437239: Recycling pathway of L1

Summary
Symbol	MSN
Name	moesin
Aliases	HEL70; epididymis luminal protein 70; membrane-organizing extension spike protein
Chromosomal Location	Xq11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MSN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between MSN and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
28287407	Melanoma	Inhibit immunity	Here, we have discovered that moesin is translationally regulated by TGF-β and is also required for optimal TGF-β signaling that promotes efficient development of iTregs. Loss of moesin impaired the development and function of both peripherally derived iTregs and in vitro-induced Tregs. Mechanistically, we identified an interaction between moesin and TGF-β receptor II (TβRII) that allows moesin to control the surface abundance and stability of TβRI and TβRII. We also found that moesin is required for iTreg conversion in the tumor microenvironment, and the deletion of moesin from recipient mice supported the rapid expansion of adoptively transferred CD8+ T cells against melanoma.

Summary
Symbol	MSN
Name	moesin
Aliases	HEL70; epididymis luminal protein 70; membrane-organizing extension spike protein
Chromosomal Location	Xq11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MSN in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.66	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MSN
Name	moesin
Aliases	HEL70; epididymis luminal protein 70; membrane-organizing extension spike protein
Chromosomal Location	Xq11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MSN in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.103	0.714
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.67	0.849
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.303	0.901
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.235	0.457
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.38	0.889
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.054	0.988
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.061	0.914
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.076	0.976
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.229	0.936
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.162	0.626
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.794	0.627
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.422	0.0025

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MSN in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	2.7	-2.7	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	3.4	-3.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MSN
Name	moesin
Aliases	HEL70; epididymis luminal protein 70; membrane-organizing extension spike protein
Chromosomal Location	Xq11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MSN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MSN
Name	moesin
Aliases	HEL70; epididymis luminal protein 70; membrane-organizing extension spike protein
Chromosomal Location	Xq11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MSN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MSN. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MSN
Name	moesin
Aliases	HEL70; epididymis luminal protein 70; membrane-organizing extension spike protein
Chromosomal Location	Xq11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MSN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MSN
Name	moesin
Aliases	HEL70; epididymis luminal protein 70; membrane-organizing extension spike protein
Chromosomal Location	Xq11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MSN expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MSN
Name	moesin
Aliases	HEL70; epididymis luminal protein 70; membrane-organizing extension spike protein
Chromosomal Location	Xq11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MSN and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MSN
Name	moesin
Aliases	HEL70; epididymis luminal protein 70; membrane-organizing extension spike protein
Chromosomal Location	Xq11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MSN collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MSN